جست‌وجوی استاد و پژوهشگر

Seppo Meriمشاهده پروفایل

پژوهشگر

• Biomedical Sciences
• Complement System
• Immunology
• +۴ مورد دیگر

Seppo Meri is a Research Director at the Department of Bacteriology and Immunology, University of Helsinki, and a supervisor in the Doctoral Programmes in Biomedicine, Clinical Research, and Population Health. His research focuses on the complement system, immunology, nephrology, and infectious diseases, with a particular emphasis on diseases like C3 glomerulopathy, malaria, and rheumatoid arthritis. He has led major projects funded by the Sigrid Jusélius Foundation, Finnish Academy, and Magnus Ehrnrooth Foundation, including studies on complement dysregulation, vaccine development, and cancer progression. Projects: Juselius 2025-2028 (€73,000), Malaria Mechanisms (2025-2026), Magnus Ehrnrooth 2024-2026 (€20,000) His work explores the intersection of inflammation, complement activation, and disease mechanisms in conditions like Alzheimer’s, atherosclerosis, and post-transplant complications. Key trends include complement-targeted therapies and microbial immune evasion strategies. Scientific awards include the ECN Gold Medal (2019), Labquality Prize (2014), and membership in The Finnish Academy of Sciences (2009). He has supervised students such as Lokki, A.I. (2023-2024) and Kant, R. (2023-ongoing), while contributing to malaria control trials in Tanzania and complement research in rare diseases.

• Genetic Epidemiology
• Cardiovascular Disease
• Hyperlipidemia
• +۳ مورد دیگر

Pia R. Kamstrup is a Clinical Professor at the Department of Clinical Medicine, University of Copenhagen, and heads the Department of Clinical Biochemistry at Copenhagen University Hospital - Herlev and Gentofte. Her educational background includes: DMSc (Doctor Medicinae) from University of Copenhagen (awarded August 23, 2024) PhD from University of Copenhagen (awarded December 12, 2008) MD from University of Copenhagen (awarded January 17, 2002) Dr. Kamstrup's research focuses on genetic epidemiology, particularly genetically determined heritable hyperlipidemia and cardiovascular disease. She is renowned for her work on genetically determined high lipoprotein(a) and its associated morbidity and mortality. Her research utilizes large population studies including the Copenhagen General Population Study (N~150,000) and the Copenhagen Baby Heart Study (N~25,000), where she serves on the steering committees. Her work bridges clinical biochemistry with genetic epidemiology to understand cardiovascular risk factors at a population level. Her recent publications demonstrate significant contributions to understanding lipoprotein(a) in cardiovascular disease, dementia risk, and cardiac biomarker diagnostics. Her research shows consistent focus on translating genetic findings into clinical applications for cardiovascular risk assessment. Dr. Kamstrup has received lecture honoraria from the American Heart Association, Medscape, Novartis, PCSK9 Forum, and Physicians' Academy for Cardiovascular Education. She has served as a consultant for Amgen (past), Novartis (past), Lilly (present), and Silence Therapeutics (present). Her research has been supported by funding from Gangstedfonden, IMK Almene Fund, Novo Nordisk Foundation (as co-applicant), and The Danish Council for Independent Research - Medical Sciences. She is actively involved in the Lp(a) International Taskforce (ITF) initiative, contributing to global efforts in understanding and addressing lipoprotein(a)-related cardiovascular risks. She collaborates extensively with researchers across Denmark and internationally in cardiovascular genetics and epidemiology.

• Lipoprotein metabolism
• HDL (High-Density Lipoprotein) research
• Atherosclerosis
• +۷ مورد دیگر

Mary Sorci Thomas, PhD is a Professor with Tenure in the Department of Medicine, Division of Endocrinology at the Medical College of Wisconsin and in the Department of Pathology Section on Lipid Sciences at Wake Forest University School of Medicine. She serves as Associate Director of the Cardiovascular Center and Associate Program Director of the CVC T32 Training Program at MCW. Dr. Sorci Thomas is an internationally recognized expert in lipoprotein metabolism and HDL research with over 30 years of continuous NIH funding. Dr. Sorci Thomas's research program focuses on the structural and functional properties of apolipoprotein A-I and HDL, with particular emphasis on how these relate to cholesterol transport, inflammation, and atherosclerosis. Her work has provided fundamental insights into the mechanisms of HDL biogenesis, the role of specific apolipoprotein domains in LCAT activation, and the relationship between HDL function and immune regulation. Her laboratory employs a multidisciplinary approach combining protein chemistry, molecular biology, cell culture, and animal models to investigate these processes. Analysis of Dr. Sorci Thomas's recent publications reveals a continued focus on HDL structure-function relationships, with increasing attention to the connections between lipid metabolism, inflammation, and vascular biology. Her work spans basic mechanistic studies of apolipoprotein structure to translational investigations of HDL function in disease processes, demonstrating a consistent trajectory of high-impact research in lipoprotein biology. Established Investigator, American Heart Association (1994-1999) Women's Mentoring Award, American Heart Association (2002) Special Recognition Award, Arteriosclerosis, Thrombosis and Vascular Biology Council (2002) Chair, Gordon Conference on Lipoprotein Metabolism (2006) Chair, Kern Aspen Lipid Meeting (2010-Present) Co-Chair, Atherosclerosis, Thrombosis and Vascular Biology Council of AHA (2016-2022) Dr. Sorci Thomas has mentored numerous students, postdocs, and junior faculty throughout her career. As Associate Program Director of the CVC T32 Training Program at MCW, she continues to play an active role in training the next generation of cardiovascular researchers. Her mentorship extends beyond her own laboratory through her leadership roles in national organizations and scientific review panels.

• Alzheimer's Disease
• Cognitive Aging
• Sex Differences in Neurodegeneration
• +۲ مورد دیگر

Dr. Erin Sundermann is an Associate Adjunct Professor in the Department of Psychiatry at UC San Diego's Health Sciences division. Her research program focuses on cognitive neuroscience with emphasis on Alzheimer's disease, cognitive aging, and HIV-associated neurocognitive disorders. She investigates sex differences in disease manifestation, biomarker discovery, and neuropathological mechanisms. Research Interests: Her work spans three interconnected domains: Sex-specific biomarkers and risk factors for Alzheimer's disease Neurocognitive manifestations in HIV populations Modifiable risk factors at the intersection of vascular health, inflammation, and neurodegeneration She employs neuroimaging, molecular analysis, and cognitive phenotyping to understand how biological sex modifies disease trajectories. Publication Trends: Dr. Sundermann maintains high research productivity, with recent publications (2024-2025) demonstrating: Advanced biomarker studies using tau-PET and inflammatory markers Longitudinal analyses of sex hormone-cognition relationships HIV-Alzheimer's comorbidity investigations Focus on underrepresented populations in neurodegenerative research Her work consistently integrates clinical neuroscience with public health perspectives. Active Research Funding: NIH R01AG074221: 'Sex Differences in the Clinical Expression of Alzheimer's Disease Neuropathology' (2021-2026)

Jason McDermottمشاهده پروفایل

دانشیار

• Systems biology
• Network inference
• Data integration
• +۱۰ مورد دیگر

Jason McDermott is a senior research scientist and Team Lead for Systems Biology at Pacific Northwest National Laboratory (PNNL), with an Affiliate Associate Professor appointment in the Department of Molecular Microbiology and Immunology at Oregon Health & Science University (OHSU). His work bridges computational and experimental biology, focusing on data integration, network analysis, and systems-level understanding of biological processes. McDermott earned his BA in Biology from Reed College in 1993, PhD in Structural Virology from OHSU in 2000, and completed post-doctoral training in Bioinformatics at the University of Washington in 2006. His research spans cancer biology, host-pathogen interactions, microbiome science, and computational prediction of protein functions. His work integrates high-throughput omics data to develop systems biology models, with particular emphasis on biomarker discovery, network inference, and pathway analysis. Recent publications demonstrate his leadership in applying multi-omics approaches to understand viral infections, soil microbial communities, cancer mechanisms, and metabolic diseases. His research portfolio shows consistent focus on developing computational methods for biological data integration and analysis, with applications across diverse domains from infectious disease to cancer biology and environmental microbiology. 1997 Sears Fellowship Award (OHSU) 1998 Tartar Fellowship Award (OHSU) 2008 Analytics Challenge Winner (Supercomputing 2008) McDermott actively collaborates with experimental biologists, statisticians, and mass spectrometrists to develop and apply computational methods. He has made significant contributions to the Clinical Proteomic Tumor Analysis Consortium (CPTAC), particularly in ovarian cancer research, where he serves as chair of both the biology working group and data analysis working group. His work often involves interdisciplinary teams focused on translating computational insights into biological understanding.

Carrie Wieseمشاهده پروفایل

استادیار

• Cardiometabolic physiology
• Sex differences in disease
• Genetic sex impact on physiology
• +۴ مورد دیگر

Dr. Carrie Wiese is an Assistant Professor in the Department of Pharmacology at the LSU Health Sciences Center School of Medicine in New Orleans, Louisiana. Her research focuses on the impact of sex components—gonads and sex chromosomes—on cardiometabolic physiology, with particular emphasis on how genetic sex influences disease mechanisms. Education: Postdoctoral Fellowship in Human Genetics, University of California, Los Angeles (2024) Ph.D. in Molecular Physiology & Biophysics, Vanderbilt University (2019) B.S. in Molecular Biology, University of Tennessee, Chattanooga (2008) Dr. Wiese's research investigates how the sex chromosome complement (XX and XY) causes unequal gene dosage through two mechanisms: 1) the presence and absence of Y chromosome genes and 2) a subset of X chromosome genes escaping X chromosome inactivation, leading to higher expression in XX cells than XY cells. These mechanisms modulate cellular function and impact whole-body physiology. Her current research projects include utilizing multi-omics approaches to assess the impact of gonadal and genetic sex on hepatic function during fatty liver disease, evaluating the impact of sex on epigenetic regulation in atherosclerosis, and determining the role of X chromosome gene Kdm6a in brown adipose energy metabolism. Dr. Wiese has published extensively on sex differences in cardiometabolic disease, with recent publications focusing on X chromosome dosage effects, sex differences in lipid metabolism, and the role of specific genes in sex-biased disease phenotypes. Her work bridges basic genetic mechanisms with clinical implications for understanding sex differences in disease susceptibility and treatment response. Scientific Awards: No specific awards mentioned in the provided text Dr. Wiese is actively mentoring graduate students and post-doctoral fellows in her laboratory. Her research has significant implications for understanding sex differences in disease mechanisms and developing more personalized approaches to treating cardiometabolic disorders. She is currently accepting new graduate students and post-doctoral fellows to join her research team. Dr. Wiese's laboratory is part of the Cardiovascular Center at LSU Health Sciences Center, where she collaborates with other researchers investigating cardiovascular disease mechanisms and potential therapeutic approaches.

• Biostatistics
• Cardiovascular Research
• Clinical Epidemiology
• +۲ مورد دیگر

Johan Westerbergh serves as a Statistician at the Uppsala Clinical Research Center (UCR), part of Uppsala University. His work focuses on biostatistical analysis within large-scale clinical studies, particularly cardiovascular and epidemiological research. His research spans cardiovascular epidemiology , clinical trial methodology , and medical statistics , with emphasis on atrial fibrillation, myocardial infarction, and anticoagulation therapy outcomes. Recent publications demonstrate expertise in registry-based analyses (SWEDEHEART), biomarker validation, and risk stratification models across cardiology, nephrology, and oncology domains. Analysis of his publication trends reveals consistent contributions to high-impact cardiology journals, with increasing focus on machine learning applications in medical imaging (2023) and sex-specific outcome analyses in anticoagulation therapy. His collaborative work frequently involves multinational clinical trials including ARISTOTLE and PLATO. Professional collaborations span Uppsala University's medical faculty, SWEDEHEART registry investigators, and international research consortia. Current projects include pediatric acute kidney injury meta-analyses and deep learning applications in coronary plaque characterization.